Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP‐005 study recurrent glioblastoma cohort

Documenti analoghi

• Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple‐negative breast cancer: Results from the triple‐negative breast cancer cohort of the phase 2 LEAP‐005 Study
  di: Hyun Cheol Chung, et al.
  Pubblicazione: (2024)
• Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum‐containing chemotherapy: Post hoc analysis of KEYNOTE‐052 and LEAP‐011
  di: Peter H. O’Donnell, et al.
  Pubblicazione: (2024)
• Combination of Lenvatinib and pembrolizumab as neoadjuvant treatment for BRAF negative anaplastic thyroid cancer
  di: Zhao Jie, et al.
  Pubblicazione: (2025)
• Real‐world outcomes for patients with pleural mesothelioma: A multisite retrospective cohort study
  di: Kar Ven Cavan Chow, et al.
  Pubblicazione: (2024)
• Aletheia: Physics-Conditioned Localized Artifact Attention (PhyLAA-X) for End-to-End Generalizable and Robust Deepfake Video Detection
  di: Ghori, Devendra
  Pubblicazione: (2026)